Mumbai Supriya Lifescience Ltd., a cGMP-compliant company with a solid track record in API manufacturing and an emphasis on products from a range of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic, has released the unaudited financial statements for the Q2FY25 results. The corporation has expanded its operations to over 86 countries worldwide.
Key Consolidated Financial Highlights for Q2FY25:
| Particulars | Q2 FY25 | Q2 FY24 | Y-o-Y |
| Revenues (in Rs Cr) | Rs. 166.1 | Rs. 140.1 | 18.6% |
| Gross Profit (in Rs Cr) | Rs. 120.13 | Rs.78.46 | 53.1% |
| EBITDA (in Rs Cr) | Rs. 64.72 | Rs. 31.75 | 103.8% |
| EBITDA Margin | 39.0% | 22.7% | +1630 Bps |
| PAT (in RsCr) | Rs. 46.15 | Rs. 23.88 | 93.2% |
| PAT Margin | 27.8% | 17.0% | +1074 Bps |
| EPS (in Rs) | 5.71 | 2.97 |
Key Consolidated Financial Highlights for H1FY25:
| Particulars | H1 FY25 | H1 FY24 | Y-o-Y |
| Revenues (in Rs Cr) | Rs. 326.7 | Rs. 272.1 | 20.1% |
| Gross Profit (in Rs Cr) | Rs. 232.1 | Rs.163.2 | 42.2% |
| EBITDA (in Rs Cr) | Rs. 127.2 | Rs. 75.9 | 67.5% |
| EBITDA Margin | 38.9% | 27.9% | +1103 Bps |
| PAT (in RsCr) | Rs. 907.9 | Rs. 523.9 | 73.3% |
| PAT Margin | 27.8% | 19.3% | +853 Bps |
| EPS (in Rs) | 11.25 | 6.51 |
Important Takeaways for Q2 FY25:
- During the second quarter of FY25, Supriya Lifescience Ltd. reported a notable rise in revenue, rising 18.6% year over year to Rs. 166.1 crore.
- in contrast to Q2 FY24’s Rs. 140.1 crore The gross profit for the second quarter of FY25 was Rs. 120.13 crore, up 53.1% from Rs. 78.46 crore in the second quarter of FY24.
- In Q2 FY24, EBITDA was Rs. 31.75 crore with an EBITDA margin of 22.7%, but in Q2 FY25, EBITDA was Rs. 64.72 crore with an EBITDA margin of 39.0%. This is a 103.8% YoY increase.
- Q2 FY25’s Profit After Tax (PAT) was Rs 46.15 crore, up from Rs 23.88 crore in Q2 FY24. In Q2 FY25, the PAT Margin was 27.8%, while in Q2 FY24, it was 17.0%.
- The business increase in Q2 was powered by the analgesic and anaesthetic segment, which contributed 54.9% of sales, compared to 50.0% in Q2FY24
- Compared to 7.2%, the anti-asthmatic category contributed 9.2%.
- In H1FY25, European markets accounted for 45% of our company’s sales, up from 39% in H1FY24.
- Three ANDA projects for anaesthetic therapy have been started, and the business is also working on ANDA projects for vitamins and antihypertensive medications. The use of capacity has rapidly grown from 47% in FY22 after a new
- FY24 capacity expansion to 86%. The corporation has purchased three distinct land lots close to major operations in order to assist the future expansion of different business sectors.
- With more than 1,700 clients in more than 128 countries, Supriya Lifescience Ltd. is still growing its global presence. In order to guarantee continued growth and additional expansion by acquiring new clients, the business has These geographical areas were thoughtfully divided among its committed sales staff.
Speaking on the findings, Dr. Satish Wagh, Executive Chairman & WTD, Supriya Lifescience Ltd., stated, “Our dedication to innovation through R&D is paving the way for sustained growth and expansion.” With the opening of our state-of-the-art research and development facility at Lote
We’re concentrating on developing new products and CMO/CDMO prospects to enhance our current portfolio at Parshuram and the soon-to-be Ambernath plant. Along with growing our worldwide footprint in strategic areas, we’re collaborating closely with sales and regulatory teams to attract new clients, especially in regulated industries. Our ability to manage intricate chemical processes is demonstrated by our recent exclusive 10-year deal with a top European company, which paves the way for future possibilities of this nature. As we improve our infrastructure, such as raising Lote Parshuram’s capacity to 1,020 KL by Q3 FY25, we’re laying the groundwork for a more robust future.”
Disclaimer According to relevant securities regulations, some comments in this “Document” that discuss the company’s goals, forecasts, estimates, expectations, plans, or predictions, as well as market circumstances or events, may be “forward-looking statements.” rules. There may be significant differences between stated or suggested outcomes, performance, or accomplishments and actual ones. The company does not commit to updating or revising forward-looking statements to reflect events or developments that occur after the date hereof, or to reflect the occurrence of unforeseen events or developments.
About Supriya Lifescience Ltd.:
Established in 1987, Supriya Lifescience Ltd. is a globally recognised manufacturer of active medicinal ingredients. Health Canada has certified our state-of-the-art facility. NMPA, USFDA, EDQM, and EUGMP. Our plant is situated in Khed, District Ratnagiri, while the company’s headquarters are in Mumbai, India. Strong R&D, eight active CEPs, and fourteen active USDMFs support our worldwide compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, and ANVISA). Our primary business is guided by ethical ideals and EHS regulations. The company’s main goal is to create APIs and intermediates for inventors and generic businesses. Additionally, we only work with partners in our role as CMOs.